High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome.

doi:10.1016/j.jtho.2020.03.005

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jul 2020

Mezquita Laura, Jové Maria, Nadal Ernest, Kfoury Maria, Morán Teresa, Ricordel Charles, Dhooge Marion, Tlemsani Camille, Léna Hervé, Teulé Alex, Álvarez Jose-Valero, Raimbourg Judith, Hiret Sandrine, Lacroix Ludovic, Menéndez Mireia, Saldaña Juana, Brunet Joan, Lianes Pilar, Coupier Isabelle, Auclin Edouard, Recondo Gonzalo, Friboulet Luc, Adam Julien, Green Emma, Planchard David, Frébourg Thierry, Capellà Gabriel, Rouleau Etienne, Lázaro Conxi, Caron Olivier, Besse Benjamin

Abstract excerpt

INTRODUCTION: Actionable somatic molecular alterations are found in 15% to 20% of NSCLC in Europe. NSCLC is a tumor observed in patients with germline TP53 variants causing Li-Fraumeni syndrome (LFS), but its somatic molecular profile is unknown. METHODS: Retrospective study of clinical and molecular profiles of patients with NSCLC and germline TP53 variants. RESULTS: Among 22 patients with NSCLC and LFS (n = 23...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Europe

Share to Germ-Line Mutation

Share to Li-Fraumeni Syndrome

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins

Source

Open in PubMed

Identifiers

PMID: 32179180
DOI: 10.1016/j.jtho.2020.03.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome.PMID 32179180Read ↗

Clinical characteristics and management of Li-Fraumeni syndrome-associated lung cancer.Semantic proximity Read ↗

The Clinical and Molecular Profile of Lung Cancer Patients Harboring the TP53 R337H Germline Variant in a Brazilian Cancer Center: The Possible Mechanism of Carcinogenesis.Semantic proximity Read ↗

A dual biomarker in non-small cell lung cancer that predicts Li Fraumeni syndrome : Lung cancer and Li Fraumeni.Semantic proximity Read ↗

Synchronous Lung Adenocarcinomas With Distinct EGFR Mutations In A Patient With Li-Fraumeni SyndromeSemantic proximity Read ↗

Rare mutations in non-small-cell lung cancer.Semantic proximity Read ↗

Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations.Semantic proximity Read ↗

Personalized screening strategies for TP53 R337H carriers: a retrospective cohort study of tumor spectrum in Li-Fraumeni syndrome adult carriersSemantic proximity Read ↗

Driver gene alterations in lung adenocarcinoma: Demographic features of 2544 Chinese cases.Semantic proximity Read ↗

Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutationsSemantic proximity Read ↗

Presentation of EGFR mutations in 162 family probands with multiple primary lung cancerSemantic proximity Read ↗

Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.Semantic proximity Read ↗

Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.